Innocoll is a global commercial stage specialty pharmaceutical company with late stage development programs targeting areas of significant unmet medical need.
We develop and manufacture a range of surgical implants and topically applied healthcare products using our proprietary collagen based technologies, CollaRx®, CollaFilm ®, CollaPress™ and LiquiColl ®. Our technologies are well established and are fully biocompatible and biodegradable with a long history of safe and effective use.
Our lead pipeline products include; XaraColl, entering phase 3 for the treatment of post-operative pain, Cogenzia, entering phase 3 for the treatment of diabetic foot infections, and CollaGUARD, our adhesion barrier product entering pivotal study for the United States.
We have commercial products approved in Europe, the US, and many other ROW countries. All of our products are manufactured at our facility in Saal, Germany.
Publications show all
Innocoll has published 3 articles.
Patents show all
Clinical Trials show all
SEC Filings show all
SEC Form D Funding Events
|2013-02-04||$1,464,894||$1,464,894||Equity, Debt, Option to Acquire|
|2012-12-10||$2,000,002||$2,000,002||Equity, Debt, Option to Acquire|
|2012-07-26||$2,000,000||$2,000,000||Equity, Debt, Option to Acquire|
|2012-03-01||$1,100,031||$1,100,031||Equity, Debt, Option to Acquire|
|2011-08-31||$3,250,000||$3,250,000||Equity, Debt, Option to Acquire|
|2011-04-13||$3,250,000||$3,250,000||Equity, Debt, Option to Acquire|
|2010-12-09||$5,250,000||$5,250,000||Equity, Debt, Option to Acquire|
|2010-07-13||$5,000,000||$5,000,000||Equity, Debt, Option to Acquire|
|2010-03-24||$4,000,000||$4,000,000||Debt, Option to Acquire|
|2009-07-29||$4,000,000||$4,000,000||Debt, Option to Acquire|
- Michael Myers
Executive Officer, Director
- Rolf D. Schmidt
- Paul G. Oxholm
- Anthony Wild
- Gordon Dunn
- Kenneth E. Higgins
- Courtney Carson
- Steven A. Shallcross
- William O'Donnell
- John O'Meara
- Dennis Langer
- James Culverwell